Houston digital health platform Koda closes $7 million funding round

fresh funding

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health, which recently closed a $7 million series A. Photo courtesy Koda Health.

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

  • 79 percent reduction in terminal hospitalizations
  • 20 percent decrease in inpatient length of stay
  • 51 percent increase in hospice use among decedents
  • Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.

From Your Site Articles
Insight Surgery, a personalized orthopedic surgery technology company with its U.S. business operations based in Houston, has closed a series A. Photo courtesy Insight Surgery.

TMC med-tech company closes $2.5M series A, plans expansion

fresh funding

Insight Surgery, a United Kingdom-based startup that specializes in surgical technology, has raised $2.5 million in a series A round led by New York City-based life sciences investor Nodenza Venture Partners. The company launched its U.S. business in 2023 with the opening of a cleanroom manufacturing facility at Houston’s Texas Medical Center.

The startup says the investment comes on the heels of the U.S. Food and Drug Administration (FDA) granting clearance to the company’s surgical guides for orthopedic surgery. Insight says the fresh capital will support its U.S. expansion, including one new manufacturing facility at an East Coast hospital and another at a West Coast hospital.

Insight says the investment “will provide surgeons with rapid access to sophisticated tools that improve patient outcomes, reduce risk, and expedite recovery.”

Insight’s proprietary digital platform, EmbedMed, digitizes the surgical planning process and allows the rapid design and manufacturing of patient-specific guides for orthopedic surgery.

“Our mission is to make advanced surgical planning tools accessible and scalable across the U.S. healthcare system,” Insight CEO Henry Pinchbeck said in a news release. “This investment allows us to accelerate our plan to enable every orthopedic surgeon in the U.S. to have easy access to personalized surgical devices within surgically meaningful timelines.”

Ross Morton, managing Partner at Nodenza, says Insight’s “disruptive” technology may enable the company to become “the leader in the personalized surgery market.”

The startup recently entered a strategic partnership with Ricoh USA, a provider of information management and digital services for businesses. It also has forged partnerships with the Hospital for Special Surgery in New York City, University of Chicago Medicine, University of Florida Health and UAB Medicine in Birmingham, Alabama.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A

cha-ching

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Shreyans Chopra, founder of Mstack, is celebrating the close of his company's $40 million series A. Photo courtesy of Mstack

Innovative Houston chemicals manufacturing platform provider raises $40M series A

money moves

Houston-based Mstack, whose platform helps manufacturers source specialty chemicals, has raised $40 million in a series A funding round.

Lightspeed Venture Partners and Alpha Wave Incubation led the round, which includes a debt facility from HSBC Innovation Banking and money from several angel investors.

In a news release, Mstack says the infusion of cash will enable it to “double down on its mission to disrupt a historically flawed supply chain for specialty chemicals.”

This “doubling down” will include expansion of Mstack’s footprint in the U.S., Middle East, Latin America, and Asia.

“Geopolitical dynamics pose risks for supply chain disruptions in the global specialty chemicals market,” Bejul Somaia, a partner at Lightspeed, says in a news release.

“With demand for these chemicals growing rapidly, there is a need to increase R&D investments and unlock new pockets of supply,” he adds. “As the first institutional investor in Mstack, we believe that the company has tremendous potential to lead this transformation.”

Mstack, founded in 2022, currently serves four business sectors: oil and gas, coatings, water treatment, and home and personal care. The funding will enable it to move into industry segments such as agrochemicals and pharmaceuticals.

The Mstack platform gives buyers a one-stop shop for sourcing, testing, shipping, delivering, and tracking specialty chemicals.

“This new funding affirms investor confidence in our vision and technology to transform global markets. It enables us to expand geographically and intensify our R&D efforts,” Mstack founder Shreyans Chopra says.

Houston-based Citroniq Chemicals has secured its series A funding. Photo via Getty Images

Houston company secures $12M series A for decarbonization plant

money moves

A fresh $12 million round of funding will enable Houston-based Citroniq Chemicals to propel planning, design, and construction of its first decarbonization plant.

An unidentified multinational energy technology company led the series A round, with participation from Houston-based Lummus Technology Ventures and cooperation from the State of Nebraska. The Citroniq plant, which will produce green polypropylene, will be located in Nebraska.

“Lummus’ latest investment in Citroniq builds on this progress and strengthens our partnership, working together to lower carbon emissions in the plastics industry,” Leon de Bruyn, president and CEO of Lummus Technology, says in a news release.

Citroniq is putting together a decarbonization platform designed to annually capture 2 million metric tons of greenhouse gas emissions at each plant. The company plans to invest more than $5 billion into its green polypropylene plants. Polypropylene is a thermoplastic resin commonly used for injection molding.

The series A round “is just the first step in our journey towards building multiple biomanufacturing hubs, boosting the Nebraska bioeconomy by converting local ethanol into valuable bioplastics,” says Kelly Knopp, co-founder and CEO of Citroniq.

Citroniq’s platform for the chemical and plastics industries uses technology and U.S.-produced ethanol to enable low-cost carbon capture. Citroniq’s process permanently sequesters carbon into a useful plastic pellet.

Lummus Technology licenses process technologies for clean fuels, renewables, petrochemicals, polymers, gas processing and supply lifecycle services, catalysts, proprietary equipment, and digital transformation.

Prana Thoracic Inc., a Houston medical device company developing a tool for early interception of lung cancer, announced an additional $3 million in funding. Photo via Getty Images

Houston medtech startup secures additional $3M for lung cancer diagnostic tool

fresh funding

A Houston-based medtech startup with an innovative tool that's aiming to transform lung cancer intervention has closed its series A extension round.

Prana Thoracic announced an additional $3 million in funding, a raise that was oversubscribed by 30 percent, reports the company. The company's series A originally closed in March 2023 at $3 million. In August of 2022, the company secured $3 million in grant funding.

"We are grateful for the overwhelming support from our investors in this financing round. Their confidence in our mission and plan is motivating,” Joanna Nathan, CEO and co-founder of Prana Thoracic, says in a news release. “This additional funding will enable us to accelerate our efforts in bringing precision surgical solutions to lung cancer patients worldwide.”

The extension included participation from new investors, including cultivate(MD), GenHenn Capital, and Houston Angel Network, as well as from prior lead investor New World Angels. Existing investors — Johnson & Johnson Development Corp, Texas Medical Center Venture Fund, and the Cancer Prevention & Research Institute of Texas (CPRIT) — also support the company.

"We are excited to support Prana Thoracic in their mission to improve lung cancer treatment. Their innovative approach has the potential to significantly impact patient outcomes," says Dr. R. Sean Churchill, managing director of cultivate(MD), in the release.

The additional funding will support the company as it advances through its clinical and regulatory plans.

“The team has made remarkable progress in developing this novel and minimally invasive technique for lung tissue excision, which has the potential to transform the diagnosis and treatment of early-stage lung cancer," adds Dr. Edward M. Boyle, founder and director at the company. "Beyond lung applications, they are pioneering new methods to use this technology for other soft tissues and are actively exploring integration with ablation and robotic systems, aligning with the future direction of these fields."

In 2022, Nathan joined the Houston Innovators Podcast to discuss her passion for Prana Thoracic's innovation. Listen to the episode below.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

3 Houston companies land on Deloitte’s Technology Fast 500 list

trending up

Three Houston companies have made this year’s Deloitte North America Technology Fast 500 list.

The report ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The Houston companies to make the list, along with their revenue growth rates from 2021-2024, include:

  • No. 16 Action1 Corp., a provider of cybersecurity software. Growth rate: 7,265 percent
  • No. 92 Cart.com, a commerce and logistics platform. Growth rate: 1,053 percent
  • No. 312 Tellihealth, a remote health care platform. Growth rate: 244 percent

“Houston’s unique blend of entrepreneurial energy and innovation continues to strengthen the local business community, and I’m thrilled to see Houston companies honored on the 2025 Deloitte Technology Fast 500 list. Congratulations to all the winners,” said Melinda Yee, managing partner in Deloitte’s Houston office.

Action1 is no stranger to lists like the Deloitte Technology Fast 500. For instance, the company ranked first among software companies and 29th overall on this year’s Inc. 5000, a list of the country’s fastest-growing private companies. Its growth rate from 2021 to 2024 reached 7,188 percent.

Mike Walters, president and co-founder of Action1, said in August that the Inc. 5000 achievement “reflects the dedication of Action1’s global team, who continue to execute against an ambitious vision: a world where cyberattacks exploiting vulnerabilities are entirely prevented across all types of devices, operating systems, and applications.”

Atlanta-based Impericus, operator of an AI-powered platform that connects health care providers with pharmaceutical and life sciences companies, topped the Deloitte list with a 2021-24 growth rate of 29,738 percent.

“Our mission is to set the standard for ethical AI-powered physician connections to pharma resources, accelerating and expanding patient access to needed treatments,” said Dr. Osama Hashmi, a dermatologist who’s co-founder and CEO of Impiricus. “As we continue to innovate quickly, we remain committed to building ethical bridges across this vital ecosystem.”

How executive education retains your best employees + drives success

Investing in People

Hiring is tough, but retaining great people is even harder. Ask almost any manager what keeps them up at night, and the answer usually comes back to the same thing: How do we keep our best employees growing here instead of looking elsewhere?

One reliable approach has held up across industries. When people see their employer investing in their development, they’re more likely to stay, contribute, and imagine a future with the organization.

The data backs this up. Employees who take part in ongoing training are far less likely to leave, and the effect is especially strong for younger workers. One national survey found that 86% of millennials would stay with an employer that invests in their development. Companies that build a real learning culture see retention jump by 30-50%. The pattern is consistent: When people can learn and advance, they stay.

The ROI of executive education
Professional development signals value, but it also builds capability. When people have access to structured learning, they become better problem-solvers, more adaptable, and more confident leading through change.

That's the focus of Executive Education at Rice University's Jones Graduate School of Business. The portfolio is built for the realities of modern leadership: AI and digital transformation courses for teams navigating new technologies, and deeper programs in innovation and strategy for leaders sharpening long-term thinking.

“People, managers, professionals, and executives in all functional areas of business can benefit from this program,” notes Jing Zhou, Mary Gibbs Jones Professor of Management and Psychology at Rice. “We teach the fundamental principles of how to drive innovation and broaden the cognitive space.”

That perspective runs through every offering, from the Rice Advanced Management Program to the Leadership Accelerator and Leading Innovation. Each program gives participants practical tools to think strategically, work across teams and make meaningful change inside their organizations.

Building the leadership pipeline
Leadership development isn’t a perk anymore. It’s a strategic need for any organization that wants to grow and stay competitive.

Employers know this — nearly two-thirds say leadership training is essential to their success — yet employees still report feeling stalled. Reports find 74% of employees feel they aren’t reaching their potential because they lacked meaningful growth opportunities.

Rice Business designs its Executive Education programs to address that gap. The Rice Advanced Management Program, for example, supports leaders preparing for C-suite, board, or enterprise-level roles. Its format — two in-person modules separated by several weeks — gives participants space to test ideas at work, return with questions, and build on what they’ve learned. The structure fits demanding executive schedules while creating room for deeper reflection and richer peer connections.

Just as important, the program helps senior leaders align on strategy and culture. Participants develop a shared language and build stronger relationships, which translates into clearer decision-making, better collaboration, and less burnout across teams.

Houston’s advantage
Houston gives Rice Business Executive Education a distinctive edge. The city’s position in energy, healthcare, logistics, and innovation means participants are learning in the middle of a global business ecosystem. That proximity brings a mix of perspectives you don’t get in more siloed markets, and it pushes leaders to apply ideas to real-world problems in real time.

The expertise runs deep on campus, as well. Participants learn from faculty who are shaping conversations in their fields, not just teaching from a playbook. For many organizations, that outside perspective is a meaningful complement to in-house training — a chance to stretch thinking, challenge assumptions, and broaden leadership capacity.

Rice Business offers multiple paths into that experience, from open-enrollment programs like Leading Organizational Change, Executive Leadership for Women, or Driving Growth through AI and Digital Transformation to fully customized corporate partnerships. Across all formats, the focus is the same: education that is practical, relevant, and built for impact.

Investing in retention and results
When organizations make room for real development, the payoff shows up quickly: higher engagement, stronger leadership pipelines, and lower turnover. It also shapes the culture. People are more willing to take risks, ask better questions, and stay curious when they know learning is part of the job.

As Brent Smith, senior associate dean for Executive Education at Rice Business, explains, “There’s a layer of learning in leadership that’s about helping people adopt a leadership identity — to see themselves as the actual leader for their organization. That’s not an easy transition, but it’s the foundation of lasting success.”

For companies that want to build loyalty, deepen leadership capacity, and stay competitive in a fast-changing environment, investing in people isn’t optional. Rice Business Executive Education offers a clear path to do it well. Learn more here.

Check out upcoming programs:

Houston’s 10 most valuable startups revealed in new report

by the numbers

The Greater Houston Partnership has released its list of the 10 most valuable startups that are fueling the city’s growth and entrepreneurial energy, including industry giants like Axiom Space and Fervo Energy.

Currently, Houston hosts more than 1,300 startups in industries such as energy, life sciences, manufacturing and aerospace, according to the GHP. The list ranks its top 10 startups by valuation based on the company’s last private funding round, reflected in Pitchbook data, as of Oct. 20 of this year.

The top 10 list includes:

10. NXTClean Fuels

Valuation: $530 million

NXTClean Fuels builds biofuel refineries that produce renewable fuel by using feedstocks like cooking oil and recycled organic materials.

9. Homebase

Valuation: $660 million

HR tech company Homebase provides employee management software that helps manage and optimize timesheets, payroll and more, with over over 100,000 small businesses and 2 million hourly workers using its product.

8. Zolve

Valuation: $800 million

Zolve is a banking platform that provides customers with access to financial products that aim to be accessible, flexible, and affordable than other financial platforms.

7. Stramsen Biotech

Valuation: $807 million

Stramsen Biotech develops plant-based drug therapies that target both infectious and noninfectious diseases, which include cancer, diabetes, HIV, kidney disease and neurological issues.

6. Octagos

Valuation: $843 million

Healthtech company Octagos has developed a remote cardiac monitoring software driven by AI that helps consolidate patient data in real-time, assisting healthcare professionals in providing quicker, easier and more accurate care.

5. Fervo Energy

Valuation: $1.4 billion

Pioneering geothermal company Fervo Energy combines horizontal drilling and fiber-optic sensing to produce electricity. The company is developing its flagship Cape Station geothermal power project in Utah. The first phase of the project will supply 100 megawatts of power beginning in 2026

4.Cart.com

Valuation: $1.7 billion

Cart.com is an e-commerce giant and logistics solutions provider that was founded in 2020 and obtained unicorn status within just three years.

3. Axiom Space

Valuation: $2.1 billion

Axiom Space is one of the anchor tenants at the Houston Spaceport, and has completed four missions of sending commercial astronauts to the ISS since 2022. In 2027, the company expects to see the first section of its private space station, Axiom Station, launched into low-earth orbit.

2. Solugen

Valuation: $2.175 billion

Solugen replaces petroleum-based products with plant-derived substitutes through its Bioforge manufacturing platform.

1. HighRadius

Valuation: $3.2 billion

HighRadius uses advanced technology to automate and manage accounts receivable processes for businesses worldwide.

The GHP also released its State of Houston’s Tech and Innovation Landscape, which mapped Houston’s digital and innovation sectors. Read the full report here.

View All Listings